



Optimizing Antimicrobial Use: Clinical Pharmacists' Integral Contributions in Stewardship Initiatives

Saba Farooqui*¹, Zuha Shyma¹, Hina Aisha¹, Fathima Nashiya¹, Sajan Francis P²

1. Department of Pharmacy Practice, Karavali College of Pharmacy, Vamanjoor, Mangalore, Karnataka, India. 575028.
2. Assistant Professor, Department of Pharmacy Practice, Karavali college of Pharmacy, Vamanjoor, Mangalore, Karnataka, India. 575028.

*Corresponding author's E-mail: sabafarooqui63@gmail.com

Received: 16-09-2023; Revised: 23-10-2023; Accepted: 30-10-2023; Published on: 15-11-2023.

ABSTRACT

In hospitalized patients, infections caused by multidrug-resistant (MDR) pathogens lead to significant morbidity and mortality. Unfortunately, the era of MDR infections has brought about a decline in the availability of effective antimicrobial drugs. To counter this challenge, clinical pharmacists emerge as optimal healthcare professionals poised to devise protocols and procedures aimed at enhancing antibiotic utilization. By harnessing their expertise in drug interactions, therapeutic efficacy, and patient-centered care, clinical pharmacists can drive the development, refinement, and successful execution of ASPs. Through proactive interventions such as intravenous to oral antibiotic conversion, pharmacokinetic optimization, and vigilant monitoring, they contribute to the broader goal of mitigating the impact of MDR infections, thereby elevating the quality of care for hospitalized patients.

Keywords: Antimicrobial stewardship, Clinical Pharmacist, Antibiotic resistance, Stewardship initiatives.

INTRODUCTION

In the evolving healthcare landscape, the multifaceted challenge posed by multidrug-resistant (MDR) pathogens requires a concerted effort from various healthcare disciplines. The critical need to combat infections caused by these resilient pathogens, such as *Escherichia coli*, *Staphylococcus aureus*, *Pseudomonas aeruginosa*, *Acinetobacter baumannii*, *Klebsiella pneumoniae*, and *Streptococcus pneumoniae*, has underscored the urgency for effective interventions.¹ The year 2019 marked a distressing peak in mortality rates attributed to drug-resistant pathogens, highlighting the pressing nature of the issue.

As the availability of effective antimicrobial treatments continues to dwindle in the face of MDR infections, the focus has shifted towards a proactive approach. This approach entails a combination of enhanced infection prevention, rigorous Antimicrobial Stewardship (ASP) practices, active surveillance, and the innovation of novel antimicrobial agents. The term "antimicrobial stewardship" has gained substantial recognition in recent years, encapsulating a range of programs and strategies aimed at optimizing the judicious use of antibiotics, antivirals, and antifungals.

The establishment of effective Antimicrobial Stewardship (AMS) programs necessitates a collaborative and holistic effort. This effort involves a diverse array of experts, including infectious disease specialists, clinically proficient pharmacists specializing in infectious diseases, clinical microbiologists, IT professionals, hospital epidemiologists, and infection control specialists.² The pivotal role of clinical pharmacists and their advocacy for responsible antibiotic use cannot be understated. Working in tandem with

infectious disease physicians, they form a crucial part of the Antimicrobial Stewardship (AMSP) team.

Depending on the available resources and the healthcare context, clinical pharmacists deploy a spectrum of AMSP strategies. These strategies encompass a wide range of activities, including optimizing antibiotic administration routes, implementing prior authorization for antibiotics, utilizing pharmacokinetic and pharmacodynamic principles to fine-tune antibiotic dosing, expediting diagnostic tests, conducting prospective reviews with interventions, monitoring drug-nutrient interactions, evaluating both clinical and consumption metrics related to antibiotics, and refining dosing protocols.³

Furthermore, due to their active involvement in interdisciplinary collaborations, clinical pharmacists are uniquely positioned to develop protocols and guidelines aimed at improving the appropriateness of antibiotic use. Beyond the hospital setting, pharmacists extend their expertise to ambulatory care, long-term care facilities, and inpatient environments. Given the central role of antimicrobials in all these contexts, pharmacists possess the expertise to optimize therapeutic regimens, ensuring effective patient outcomes while mitigating the development of antibiotic resistance.³ Their contributions are invaluable in the pursuit of combating MDR pathogens and preserving the efficacy of antimicrobial agents.

"ELEVATING ANTIMICROBIAL STEWARDSHIP: THE VITAL CONTRIBUTIONS OF CLINICAL PHARMACISTS"

Clinical pharmacists play a pivotal role in antimicrobial stewardship programs, which are designed to facilitate the judicious utilization of antimicrobial medications in order to enhance patient outcomes, mitigate the emergence of



antimicrobial resistance, and conserve healthcare resources. The ensuing exposition provides a comprehensive overview of the pivotal role that clinical pharmacists undertake within antimicrobial stewardship initiatives:

- **Integral Team Members:** Clinical pharmacists are central figures within the antimicrobial stewardship team, actively collaborating alongside diverse healthcare professionals, such as infectious disease specialists, microbiologists, and infection control practitioners. The collaborative effort aims to devise and execute strategies that ensure the appropriate employment of antimicrobials.⁴
- **Assured Prescription Appropriateness:** Clinical pharmacists are entrusted with the paramount responsibility of guaranteeing the judicious prescription of antimicrobial medications. They meticulously scrutinize and evaluate antimicrobial orders, considering multifaceted aspects such as the patient's clinical status, microbiological findings, and local patterns of antimicrobial resistance. Pharmacists dispense recommendations to prescribers, thereby optimizing antimicrobial therapy through actions like dosage adjustments, de-escalation, or timely discontinuation when deemed suitable.^{4,5}
- **Continuous Antimicrobial Monitoring:** Vigilant antimicrobial monitoring within healthcare facilities is a cornerstone of clinical pharmacists' contributions. A systematic compilation and analysis of data pertaining to antimicrobial prescribing trends is executed, encompassing aspects like the appropriateness of therapy, treatment duration, and adherence to established protocols. By discerning areas necessitating enhancement, pharmacists can introduce targeted measures to fine-tune antimicrobial utilization and curtail instances of redundant or ill-suited prescriptions.⁶
- **Guideline Formulation and Implementation:** Clinical pharmacists often play a central role in the formulation and deployment of tailored antimicrobial practice guidelines specific to the facility. These meticulously crafted guidelines proffer evidence-based recommendations concerning the judicious application of antimicrobials, bearing in mind localized resistance trends and the overarching objectives of antimicrobial stewardship. Pharmacists collaboratively engage with the antimicrobial stewardship team to ensure that the guidelines remain up-to-date and are efficiently communicated to the spectrum of healthcare providers.⁶
- **Education of Healthcare Stakeholders:** The imperative to educate healthcare practitioners, patients, and the general public regarding antimicrobial stewardship and the critical significance of prudent antimicrobial utilization rests within the purview of clinical pharmacists. Their obligations encompass conducting

educational sessions, curating informative materials, and actively participating in awareness campaigns devoted to fostering comprehension and adherence to optimal practices.⁶

- **Active Role in Antimicrobial Resistance Surveillance:** Pharmacists actively partake in surveillance programs targeting antimicrobial resistance. Collaborative efforts with microbiologists and infection control practitioners yield insights into localized resistance patterns and the emergence of novel resistance tendencies. The intelligence garnered assumes paramount importance, guiding antimicrobial prescription practices and facilitating targeted interventions aimed at combatting the progression of antimicrobial resistance.

In summation, clinical pharmacists emerge as linchpins within antimicrobial stewardship endeavors, seamlessly intertwining multifaceted responsibilities to realize the overarching objectives of optimized patient care, resistance mitigation, and resource conservation.

METHOD

A systematic search was carried out spanning prominent electronic databases, which encompass PubMed, Embase, Scopus, Science Direct, and Web of Science. Employing predetermined search terms interlinked with "clinical pharmacist," "antimicrobial stewardship program," "Antibiotic resistance", and their associated synonyms, a meticulous search endeavor was executed. This investigation was confined to articles made public within the designated time frame of 2015-2022. Inclusion criteria encompassed studies shedding light on the participation of clinical pharmacists within Antimicrobial Stewardship Programs (AMSPs), meticulously examining their influence on varied aspects encompassing the use of antimicrobials, patient outcomes, and the intricate healthcare landscape. The ambit of inclusion extended to both quantitative and qualitative explorations, thereby broadening the spectrum of insights encompassed. Exclusive preference was accorded to articles that were squarely centered on initiatives led by pharmacists in the domain of antimicrobial stewardship. However, contents such as editorials, commentaries, review papers, letters to the editor, and conference summaries were intentionally excluded. To ascertain eligibility, a thorough evaluation of titles and abstracts was undertaken, and subsequent data extraction duties were undertaken by S.F.

"UNVEILING THE IMPACT: EFFECTIVENESS OF CLINICAL PHARMACIST-LED ANTIMICROBIAL STEWARDSHIP PROGRAMS"

Numerous research studies have documented the efficacy of Antimicrobial Stewardship Programs (AMSPs) spearheaded by infectious disease (ID) pharmacists across diverse nations. In South Korea, the proactive engagement of pharmacists in clinical interventions led to a notable reduction both in the count and proportion of patients subjected to unwarranted antimicrobial therapy exceeding



a duration of 3 days.⁷ Similar encouraging trends surfaced in Thailand, where ID pharmacist-led initiatives yielded a noteworthy decrease in the improper use of antibiotics. A distinctive outcome emerged wherein a greater number of antibiotics underwent de-escalation, and hospital stays were notably curtailed.⁴ On the American front, interventions spearheaded by pharmacists demonstrated their potential by forestalling a substantial 29%—122 out of 426—of potential antibiotic exposure days.⁸ An expansive cross-center investigation across four intensive care units (ICUs) within Chinese university hospitals revealed the substantial power of clinical pharmacist interventions in mitigating all-cause in-hospital mortality rates.⁹ In an insightful randomized controlled trial situated in Thailand, the role of clinical pharmacists in Antimicrobial Stewardship Programs (ASPs) was deemed non-inferior to their infectious disease counterparts in terms of clinical response—a finding that bolsters the notion that clinical pharmacists can proficiently execute ASPs as a viable alternative to physician-directed strategies.¹⁰ Turning the focus to cases of methicillin-resistant *Staphylococcus aureus* (MRSA) bacteremia, the ascendancy of clinical pharmacist-driven ASP interventions became evident. Such interventions extended the optimal duration of targeted antimicrobial dosing and expedited the administration of antimicrobial agents within a 24-hour timeframe subsequent to the detection of MRSA.¹¹ Expanding the purview to obstetrics and gynecology, interventions conducted by Nigerian pharmacists showcased remarkable enhancements in adherence to the stipulated timing and duration of surgical antibiotic prophylaxis. This proactive approach ushered in a significant reduction in prescriptions for third-generation cephalosporins—an outcome underscored by both pre- and post-intervention studies.¹²

Through the orchestration of all-encompassing Antimicrobial Stewardship Programs (ASPs) under the watchful guidance of Chinese pharmacists, a discernible increase in antibiotic consumption has been witnessed, concurrently heralding a reduction in the prevalence of drug-resistant gram-negative bacteria.¹³ Remarkably, a retrospective cohort examination within an American Trauma hospital has delineated a noteworthy dip in the count of patients subjected to inappropriate treatment of Asymptomatic Bacteriuria (ABU) as a urinary tract infection in the aftermath of interventions, in contrast to the pre-intervention phase.¹⁴ The collaborative prowess of the Department of Gastroenterology, coupled with clinical pharmacists, ushered in a significant downturn in antimicrobial consumption over the study's course.¹⁵ Illuminating another facet, a retrospective experimental inquiry helmed by a Michigan hospital pharmacist accentuated an augmented alignment with guidelines in the prescription of antibiotics for diverse infection types—ranging from upper respiratory tract infections to skin and soft tissue infections and urinary tract infections. Noteworthy headway manifested in the selection of antibiotics in congruence with stipulated guidelines,

encompassing optimal dosage and therapeutic duration.¹⁶ Emphasizing the collaborative advantage, a multicenter exploration underscored that adhering to clinical pharmacist recommendations translated into improved clinical responses in contrast to scenarios where such counsel was disregarded.¹⁷ A quasi-experimental inquiry within the realm of US hospital pharmacists, scrutinizing the stages prior to and post interventions, illuminated a pivotal breakthrough: the strategic fusion of bacteremia detection with pharmacist recommendations within ASP initiatives wielded the potential to dramatically enhance the timeliness of optimal treatment while concurrently mitigating the peril of mortality and readmission.¹⁸ A prospective delve into the Texan domain, steered by a vigilant hospital pharmacist, showcased a significant decline in the rate of fluoroquinolones prescriptions per 1000 patients. This tangible success was mirrored in the diminished incidence of improper fluoroquinolone usage.¹⁹

In instances of uncomplicated gram-negative bacteremia, the timeline for administering antibacterial treatment experienced a notable reduction—halved—courtesy of the Antimicrobial Stewardship Program (ASP) orchestrated by a local hospital, in which the active collaboration of a clinical pharmacist played a pivotal role.²⁰ A comparison with the Infectious Disease (ID) physician group spotlighted the efficacy of the "vancomycin timeout" intervention, materializing as a decline in the count of vancomycin therapy (DOT) weeks per 1000 patients. This multifaceted achievement extended to encompass a discernible curtailment in antimicrobial usage within the domain governed by pharmacist leadership.²¹ As a span of three years elapsed in the deployment of Antimicrobial Stewardship (AMS) strategies, compliance metrics scaled commendable heights of 80%, while adherence to AMS recommendations ascended to 70%. Audits and feedback mechanisms stood as corroborative evidence, attesting to the precision of antibiotic prescriptions and the unwavering allegiance to the AMS/ATT guidelines—an exemplar hailing from India's clinically guided AMS endeavor.²² The discerning observations chronicled by Nakamura et al. underscored a reduction in the utilization of piperacillin/tazobactam and carbapenems, while simultaneously witnessing a rise in the practice of de-escalation.²³ Delving into the scenario of febrile neutropenic patients, the participation of clinical pharmacists demonstrated a tangible link with heightened rates of appropriate prescriptions, all while the mortality rate remained unaltered.²⁴ Within the precincts of Japan, the participation of ID pharmacists in the tertiary-care hospital's ASP yielded a notable elevation in the rates of accurate blood-culture collection alongside a significant augmentation in therapy curtailment measures.²⁵

CONCLUSION

Pharmacists emerge as indispensable architects in the conception and execution of Antimicrobial Stewardship Programs (ASPs). Within the dynamic realm of the



Prospective Trial with Intervention and Feedback (PAIF) framework, pharmacists wield a pivotal role in perpetually assessing antibiotic regimens. This vantage point empowers them to meticulously fine-tune facets encompassing antibiotic selection, dosing precision, and the optimal span of administration. Moreover, the canvas they inhabit extends to encompass the diligent monitoring and reporting of AMS indicators, as well as the meticulous adherence to regulatory benchmarks essential for endorsement and reimbursement validation.

Amid the persistent backdrop of antibiotic resistance—casting its looming shadow over the efficacy of treating afflicted patients—pharmacists assume the mantle of pivotal team members, entrusted with safeguarding our finite pharmaceutical resources. The strategic inclusion of pharmacists, collaborating synergistically with a multidisciplinary cohort, stands as an indispensable defense against the escalating challenges entwined with infectious diseases.

The enduring integration of AMSP within the hospital ecosystem yields multifaceted dividends, manifesting as curtailed antibiotic usage and elevated clinical responses. This journey toward the long-term integration of such programs also necessitates the perpetual evolution of pharmacists. Staying attuned to the ever-evolving landscape, and fortifying their knowledge reservoirs, equips pharmacists to effectively navigate the complex terrain of a pandemic-stricken world.

Undoubtedly, the establishment of antibiotic stewardship programs assumes paramount significance in hospital settings. The bedrock of such initiatives rests upon fostering prudent and well-judged antibiotic utilization. In weaving these strategies into the fabric of healthcare frameworks, nations gain a strategic edge in surmounting their heightened susceptibility to the spiraling tide of antibiotic resistance.

As the global medical community joins hands to confront the challenge of mounting antibiotic resistance, pharmacists remain steadfast sentinels at this crucial crossroads. Their role isn't merely limited to the present; rather, it encompasses the legacy of safeguarding the future viability of antibiotic therapies for generations to come. Through their tireless efforts, astute judgment, and continuous adaptation, pharmacists illuminate the path toward a more resilient and efficacious healthcare landscape.

Grants and fundings: None received.

Acknowledgment: I would like to thank Mr. Sajan Francis P for his unwavering guidance and support.

REFERENCES

1. Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. *Lancet (London, England)* 2022; 399(10325):629–655.
2. Dellit T H, Owens R C, McGowan J E, Gerding D N, Weinstein R A, Burke J P, Huskins W C, Paterson D L, Fishman N O, Carpenter C F, Brennan P J, Billeter M, Hooton T H. Infectious Diseases Society of America, & Society for Healthcare Epidemiology of America. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. *Clinical infectious diseases: an official publication of the Infectious Diseases Society of America* 2007;44(2):159–177.
3. Barlam T F, Cosgrove E S, Abbo M L, MacDougall C, Schuetz A N, Septimus E J, Srinivasan A, Dellit H T, Falck-Ytter T Y, Fishman N O, Hamilton C W, Jenkins T C, Lipsett P A, Malani N P, May S L, Moran G J, Neuhauser M M, Newland J G, Ohl A G, Samore M H, Seo K S, Trivedi K K. Implementing an Antibiotic Stewardship Program: Guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. *Clinical infectious diseases: an official publication of the Infectious Diseases Society of America* 2016;62(10): e51–e77.
4. Jantarathaneewat, Camins, & Apisarntharak. The role of the clinical pharmacist in antimicrobial stewardship in Asia: A review. *Antimicrobial stewardship & healthcare epidemiology: ASHE* 2022;2(1): e176.
5. The role of the pharmacist in antimicrobial stewardship. (2015, August 10). Hospital Pharmacy Europe. <https://hospitalpharmacyeurope.com/news/editors-pick/the-role-of-the-pharmacist-in-antimicrobial-stewardship/>
6. Antibiotic overuse & resistance. (n.d.). Thermo Fisher Scientific. https://www.thermofisher.com/procalcitonin/wo/en/antibiotic-stewardship/antibiotic-overuse-resistance.html?cid=0se_gaw_25052021_AR3IFK
7. Song Y J, Kim M, Huh S, Lee J, Lee E, Song K H, Kim E S, Kim H B. Impact of an Antimicrobial Stewardship Program on Unnecessary Double Anaerobic Coverage Prescription. *Infection & chemotherapy* 2015;47(2):111–116.
8. Zhang X, Rowan N, Pflugeisen B M, Alajbegovic S hang. Urine culture guided antibiotic interventions: A pharmacist driven antimicrobial stewardship effort in the ED. *The American journal of emergency medicine* 2017;35(4):594–598.
9. Li Z, Cheng B, Zhang K, Xie G, Wang Y, Hou J, Chu L, Zhao J, Xu J, Lu Z, Sun H, Zhang J, Wang Z, Wu H. Pharmacist-driven antimicrobial stewardship in intensive care units in East China: A multicenter prospective cohort study. *American journal of infection control* 2017;45(9):983–989.
10. Rattanaumpawan, Upapan, & Thamlikitkul. A noninferiority cluster-randomized controlled trial on antibiotic postprescription review and authorization by trained general pharmacists and infectious disease clinical fellows. *Infection control and hospital epidemiology* 2018;39(10):1154–1162.
11. Ohashi K, Matsuoka T, Shinoda Y, Fukami Y, Shindoh J, Yagi T, Yoshimura T, Sugiyama T. Evaluation of treatment outcomes



- of patients with MRSA bacteremia following antimicrobial stewardship programs with pharmacist intervention. *International journal of clinical practice* 2018;72(3): e13065.
12. Abubakar U, Sulaiman S A S, Adesiyun A G. Impact of pharmacist-led antibiotic stewardship interventions on compliance with surgical antibiotic prophylaxis in obstetric and gynecologic surgeries in Nigeria. *PLoS one* 2019;14(3): e0213395.
 13. Wang H, Wang H, Yu X, Zhou H, Li B, Chen G, Ye Z, Wang Y, Cui X, Zheng Y, Zhao R, Yang H, Wang Z, Wang P, Yang C, Liu L. Impact of antimicrobial stewardship managed by clinical pharmacists on antibiotic use and drug resistance in a Chinese hospital, 2010-2016: a retrospective observational study. *BMJ open* 2019;9(8): e026072.
 14. James, D, & Lopez, L. Impact of a pharmacist-driven education initiative on treatment of asymptomatic bacteriuria. *American journal of health-system pharmacy: AJHP: official journal of the American Society of Health-System Pharmacists* 2019;76(Supplement_2): S41–S48.
 15. Du Y, Li J, Wang X, Peng X, Wang X, He W, Li Y, Wang X, Yang Q, Zhang X. Impact of a Multifaceted Pharmacist-Led Intervention on Antimicrobial Stewardship in a Gastroenterology Ward: A Segmented Regression Analysis. *Frontiers in pharmacology* 2020; 11:442.
 16. Westerhof R L, Dumkow E L, Hanrahan L T, McPharlin S M, Egwuatu N E. Outcomes of an ambulatory care pharmacist-led antimicrobial stewardship program within a family medicine resident clinic. *Infection control and hospital epidemiology* 2021;42(6):715–721.
 17. Zhang J, Li X, He R, Zheng W, Kwong J S, Lu L, Tianyi L T, Huang R, He M, Li X, Wang X, Fang Q, Wei L, Liu Y, Chen S, Qin X, Xie J. The Effectiveness of Clinical Pharmacist-Led Consultation in the Treatment of Infectious Diseases: A Prospective, Multicenter, Cohort Study. *Frontiers in pharmacology* 2020;11: 575022.
 18. Mahrous A J, Thabit A K, Elarabi S, Fleisher J. Clinical impact of pharmacist-directed antimicrobial stewardship guidance following blood culture rapid diagnostic testing. *The Journal of hospital infection* 2020;106(3): 436–446.
 19. Lin K, Zahlanie Y, Ortwine J K, Mang N S, Wei W, Brown L S, Prokesch C B. Decreased Outpatient Fluoroquinolone Prescribing Using a Multimodal Antimicrobial Stewardship Initiative. *Open forum infectious diseases* 2020;7(6): ofaa182.
 20. Fukuda T, Tanuma K, Iio S, Saito J, Komura M, Yamatani A. Impact of a Pharmacist-Led Antimicrobial Stewardship Program on the Number of Days of Antimicrobial Therapy for Uncomplicated Gram-Negative Bacteremia in a Community Hospital. *Cureus* 2021;13(4): e14635.
 21. Hasegawa S, Tagashira Y, Murakami S, Urayama Y, Takamatsu Nakajima A, Honda H. Antimicrobial Time-Out for Vancomycin by Infectious Disease Physicians Versus Clinical Pharmacists: A Before-After Crossover Trial. *Open forum infectious diseases* 2021;8(6): ofab125.
 22. Nakamura S, Arima T, Tashiro R, Yasumizu S, Aikou H, Watanabe E, Nakashima T, Nagatomo Y, Kakimoto I, Motoya T. Impact of an antimicrobial stewardship in a 126-bed community hospital with close communication between pharmacists working on post-prescription audit, ward pharmacists, and the antimicrobial stewardship team. *Journal of pharmaceutical health care and sciences* 2021;7(1):25.
 23. Nampoothiri V, Sudhir A S, Joseph M A, Mohamed Z, Menon V, Charani E, Singh S. Mapping the Implementation of a Clinical Pharmacist-Driven Antimicrobial Stewardship Programme at a Tertiary Care Centre in South India. *Antibiotics (Basel, Switzerland)* 2021;10(2): 220.
 24. Jantarathaneewat K, Montakantikul P, Webern D J, Nanthapaisal S, Rutjanawech S, Apisarntharak A. Impact of an infectious diseases pharmacist-led intervention on antimicrobial stewardship program guideline adherence at a Thai medical center. *American journal of health-system pharmacy: AJHP: official journal of the American Society of Health-System Pharmacists* 2022;79(15): 1266–1272.
 25. Uda A, Ebisawa K, Sakon H, Kusuki M, Izuta R, Yahata M, Yano I, Miyara T. Sustained Improvements in Antimicrobial Therapy and Clinical Outcomes following a Pharmacist-Led Antimicrobial Stewardship Intervention: Uncontrolled Before-After Study. *Journal of clinical medicine* 2022;11(3): 566.

Source of Support: The author(s) received no financial support for the research, authorship, and/or publication of this article.

Conflict of Interest: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

For any questions related to this article, please reach us at: globalresearchonline@rediffmail.com

New manuscripts for publication can be submitted at: submit@globalresearchonline.net and submit_ijpsrr@rediffmail.com

